Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 393

1.

Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease.

Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, Schmansky NJ, Greve DN, Salat DH, Buckner RL, Fischl B; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 Aug;132(Pt 8):2048-57. doi: 10.1093/brain/awp123. Epub 2009 May 21.

2.

Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve.

Querbes O, Aubry F, Pariente J, Lotterie JA, Démonet JF, Duret V, Puel M, Berry I, Fort JC, Celsis P; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 Aug;132(Pt 8):2036-47. doi: 10.1093/brain/awp105. Epub 2009 May 12.

3.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

4.

MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.

Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 Apr;132(Pt 4):1067-77. doi: 10.1093/brain/awp007. Epub 2009 Feb 27.

5.

Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Curr Alzheimer Res. 2009 Aug;6(4):347-61.

6.

Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.

Davatzikos C, Xu F, An Y, Fan Y, Resnick SM.

Brain. 2009 Aug;132(Pt 8):2026-35. doi: 10.1093/brain/awp091. Epub 2009 May 4.

7.

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.

Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ.

Neurology. 2008 Jan 15;70(3):191-9. doi: 10.1212/01.wnl.0000287091.57376.65.

PMID:
18195264
8.

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.

Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2015 Nov;138(Pt 11):3373-85. doi: 10.1093/brain/awv267. Epub 2015 Sep 15.

9.

Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.

Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Arch Gen Psychiatry. 2011 Sep;68(9):961-9. doi: 10.1001/archgenpsychiatry.2011.96.

PMID:
21893661
10.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

11.

Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.

Dong A, Toledo JB, Honnorat N, Doshi J, Varol E, Sotiras A, Wolk D, Trojanowski JQ, Davatzikos C; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2017 Mar 1;140(3):735-747. doi: 10.1093/brain/aww319.

PMID:
28003242
12.

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K.

Lancet Neurol. 2009 Jul;8(7):619-27. doi: 10.1016/S1474-4422(09)70139-5. Epub 2009 Jun 10.

PMID:
19523877
13.

Early detection of Alzheimer's disease using MRI hippocampal texture.

Sørensen L, Igel C, Liv Hansen N, Osler M, Lauritzen M, Rostrup E, Nielsen M; Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing.

Hum Brain Mapp. 2016 Mar;37(3):1148-61. doi: 10.1002/hbm.23091. Epub 2015 Dec 21.

PMID:
26686837
14.

Automated MRI measures predict progression to Alzheimer's disease.

Desikan RS, Cabral HJ, Settecase F, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, Schmansky NJ, Salat DH, Fischl B; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1364-74. doi: 10.1016/j.neurobiolaging.2010.04.023. Epub 2010 Jun 8.

15.
16.

Semantic memory activation in amnestic mild cognitive impairment.

Woodard JL, Seidenberg M, Nielson KA, Antuono P, Guidotti L, Durgerian S, Zhang Q, Lancaster M, Hantke N, Butts A, Rao SM.

Brain. 2009 Aug;132(Pt 8):2068-78. doi: 10.1093/brain/awp157. Epub 2009 Jun 10.

17.

Improved prediction of Alzheimer's disease with longitudinal white matter/gray matter contrast changes.

Grydeland H, Westlye LT, Walhovd KB, Fjell AM.

Hum Brain Mapp. 2013 Nov;34(11):2775-85. doi: 10.1002/hbm.22103. Epub 2012 Jun 5.

PMID:
22674625
18.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
19.

Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia.

Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, Miller BL, Weiner MW.

Brain. 2007 Apr;130(Pt 4):1159-66. Epub 2007 Mar 12.

20.

Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.

Velayudhan L, Proitsi P, Westman E, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Soininen H, Spenger C, Hodges A, Powell J, Lovestone S, Simmons A; dNeuroMed Consortium.

J Alzheimers Dis. 2013;33(3):755-66. doi: 10.3233/JAD-2012-121408.

PMID:
23047370

Supplemental Content

Support Center